Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition—a magnetic resonance imaging study
Key result
The TP receptor antagonist S18886 significantly reduced total vessel area and vessel wall area compared to control in a rabbit model of aortic atherosclerosis (P<0.05).
Why the study?
Does S18886 reduce atherosclerotic plaque size and improve composition in a rabbit model of aortic atherosclerosis?
Population
New Zealand White rabbits with an experimental model of established aortic atherosclerosis (n=10)
Comparison
S18886 (TP receptor antagonist) vs Control
Design
Preclinical, Randomized
Authors
Discussion
Loading...
Member takes
Implication
Does not support clinical use; leaves open translation of TP receptor antagonism to human atherosclerosis.
Study Design
Type
RCT (n=10)
Randomization
randomized
Structured PICO
Does S18886 reduce atherosclerotic plaque size and improve composition in a rabbit model of aortic atherosclerosis?
P
Population
10 New Zealand White rabbits with established aortic atherosclerosis.
I
Intervention
S18886 (TP receptor antagonist)
C
Comparator
Control
O
Outcome
Atherosclerotic lesion progression and composition (total vessel area and vessel wall area by MRI)surrogate
Main Result
p-value: p=<0.05
Inhibition of the TP receptor by S18886 regresses advanced atherosclerotic plaques and promotes a stable phenotype in a rabbit model.
Cite This Study
Viles-González et al. (2005) conducted an RCT in aortic atherosclerosis (n=10). S18886 vs. control was evaluated on total vessel area (TVA) and vessel wall area (VWA) (p=<0.05). The TP receptor antagonist S18886 significantly reduced total vessel area and vessel wall area compared to control in a rabbit model of aortic atherosclerosis (P<0.05).